Apnimed IPO on Nasdaq
Analysis based on 10 articles · First reported Jul 31, 2026 · Last updated Aug 03, 2026
The successful IPO provides Apnimed with substantial capital to advance its lead candidate AD109 toward potential FDA approval, strengthening its balance sheet and funding ongoing clinical development. The offering's upsizing and full exercise of the overallotment option indicate strong investor demand for a company addressing a large unmet need in obstructive sleep apnea, which may positively influence sentiment in the sleep-disorder therapeutics space.
Apnimed, a late-stage clinical pharmaceutical company focused on oral therapies for sleep-related breathing disorders, completed its upsized initial public offering on the Nasdaq Global Select Market. The company priced 12 million shares at $16.00 per share on July 30, 2026, and subsequently closed the offering on August 3, 2026, after underwriters fully exercised their option to purchase an additional 1.8 million shares, bringing total shares sold to 13.8 million. Gross proceeds totaled $220.8 million. The offering was managed by Meritz Securities, Evercore ISI, Cantor, and LifeSci Capital as joint book-running managers. Apnimed's lead product candidate, AD109, has completed two Phase 3 trials for obstructive sleep apnea, and its New Drug Application has a PDUFA goal date of February 28, 2027.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard